Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint

Eur Respir J. 2024 May 2;63(5):2302210. doi: 10.1183/13993003.02210-2023. Print 2024 May.

Abstract

Rifampicin is used for the treatment of Mycobacterium avium complex pulmonary disease, but pharmacokinetic and pharmacodynamic studies suggest that rifampicin cannot have therapeutic utility. We need to find better alternatives, using PK-PD science. https://bit.ly/3PUGvbV

Publication types

  • Letter
  • Editorial

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Lung Diseases / drug therapy
  • Lung Diseases / microbiology
  • Mycobacterium avium Complex* / drug effects
  • Mycobacterium avium-intracellulare Infection* / drug therapy
  • Rifampin* / therapeutic use
  • Treatment Outcome

Substances

  • Rifampin
  • Anti-Bacterial Agents